Physician profile
Efrain Garcia
NPI 1447239496
$16,945.58
in general payments reported to CMS, 2019-2025
20 companies · $4,614 in 2025
The $4,614 reported for 2025 was more than what 90% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,828 · 2020: $4,445 · 2021: $3,301 · 2022: $570 · 2023: $448 · 2024: $1,740 · 2025: $4,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,050 · Food and Beverage: $1,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,050.00 |
| Food and Beverage | $1,752.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $8,119.50 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $6,869.97 | 2019-2025 | Yeztugo, Biktarvy |
| Janssen Biotech, INC. | $606.94 | 2019-2023 | Symtuza |
| Kowa Pharmaceuticals America, INC. | $454.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $155.78 | 2019-2024 | Lagevrio |
| Janssen Products, LP | $149.94 | 2019-2022 | |
| Emd Serono, INC. | $85.19 | 2019 | |
| Amarin Pharma, INC. | $83.56 | 2019 | |
| Intuitive Surgical, INC. | $75.86 | 2023 | Da Vinci Surgical System |
| Napo Pharmaceuticals INC | $70.54 | 2019-2020 | |
| Amgen INC. | $61.62 | 2019 | |
| Melinta Therapeutics, LLC | $54.14 | 2019 | |
| Smith+Nephew, INC. | $47.77 | 2019 | |
| Medtronic Vascular, INC. | $33.23 | 2019 | |
| Mylan Pharmaceuticals INC. | $32.10 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.48 | 2025 | Camzyos |
| Glaxosmithkline, LLC. | $20.88 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrain Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.